Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials
Sign Up to like & getrecommendations! Published in 2018 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000000467
Abstract: Nivolumab, a completely human programmed death-1 inhibitor antibody, was first approved by the Food and Drug Administration for patients with advanced malignant melanoma resistant to other modalities of treatment. In 2015, it received approval as… read more here.
Keywords: melanoma; nivolumab monotherapy; randomized controlled; combination ipilimumab ... See more keywords
Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series
Sign Up to like & getrecommendations! Published in 2022 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000000825
Abstract: Anti-programmed cell death protein 1 (PD1) antibodies, pembrolizumab and nivolumab, alone or in combination with ipilimumab, have become standard treatment for melanoma and multiple other malignancies. Neurological adverse effects are rare and have not been… read more here.
Keywords: adverse effects; neurological adverse; pd1 antibodies; alone combination ... See more keywords
Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.9545
Abstract: 9545Background: Combination ipi and nivolumab is approved for advanced melanoma and is in trials across oncology. Toxicity (tox) most often occurs 6-10 wks into treatment. Whether early tox is hard... read more here.
Keywords: combination; hyperacute toxicity; combination ipilimumab; toxicity combination ... See more keywords